Brenetafusp

DRUG3 trials

Sponsors

Immunocore Limited, Immunocore Ltd

Conditions

Advanced (unresectable or metastatic) melanomaAdvanced MelanomaSelect Advanced Solid Tumors

Phase 1

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Active, not recruitingNCT04262466

Immunocore LtdSelect Advanced Solid Tumors

Start: 2020-02-25End: 2027-12-01Updated: 2026-03-06

Phase 3

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

RecruitingNCT06112314

Immunocore LtdAdvanced Melanoma

Start: 2024-06-05End: 2027-10-16Target: 680Updated: 2026-02-25

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

RecruitingCTIS2023-505306-42-01

Immunocore LimitedAdvanced (unresectable or metastatic) melanoma

Start: 2024-05-08Target: 346Updated: 2026-01-27

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).

Journal of Clinical Oncology2024-06-0112 citations

A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).

Journal of Clinical Oncology2024-06-016 citations

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).

Journal of Clinical Oncology2024-06-01